| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T729 |
0-26 |
Sentence |
denotes |
10 Summary and conclusion |
| T730 |
27-132 |
Sentence |
denotes |
In summary, COVID-19 is rapidly spreading around the globe and our understanding of the virus is limited. |
| T731 |
133-255 |
Sentence |
denotes |
To date, there is no effective, approved therapy or vaccination to treat the disease or protect against its complications. |
| T732 |
256-400 |
Sentence |
denotes |
Although the lungs are considered the main target organ of SARS-CoV-2, the virus can affect many other organs, leading to multiple organ damage. |
| T733 |
401-492 |
Sentence |
denotes |
Cardiovascular injury has been noted as a protruding clinical feature in COVID-19 patients. |
| T734 |
493-634 |
Sentence |
denotes |
The dysregulation of RAAS can lead to a harmful inflammatory response and worsening of cardiovascular consequences in patients with COVID-19. |
| T735 |
635-773 |
Sentence |
denotes |
Therefore, intervention with drugs that counteract Ang II may have a potential role in preventing the deleterious cardiovascular outcomes. |
| T736 |
774-1080 |
Sentence |
denotes |
Although increased ACE2 levels may raise the concern of increased SARS-CoV-2 infectivity, we propose here that n-3 PUFAs may be beneficial rather than harmful for cardiovascular outcomes in COVID-19 patients by limiting Ang II-induced detrimental signaling and enhancing Ang (1-7) cardioprotective effects. |
| T737 |
1081-1293 |
Sentence |
denotes |
In this review we highlight the different mechanisms of cardiovascular complications secondary to COVID-19 and draw attention toward the potential roles n-3 PUFAs in mitigating these cardiovascular complications. |
| T738 |
1294-1407 |
Sentence |
denotes |
Currently, there is no direct evidence of any beneficial or deleterious effect of n-3 PUFAs in COVID-19 patients. |
| T739 |
1408-1651 |
Sentence |
denotes |
However, it is evident from the preceding discussion the dietary or non-dietary intake of n-3 PUFAs and/or their biologically active metabolites have many beneficial actions leading to prevention and management of cardiovascular complications. |
| T740 |
1652-2115 |
Sentence |
denotes |
N-3 PUFAs and/or their biologically active metabolites have the potential to modulate many of the adverse effects of an exaggerated immune response, inactivate enveloped viruses, enhance macrophage phagocytic capacity, ameliorate coagulopathy, modify cell signaling and gene expression, shift the pattern of the lipid metabolites produced under stress conditions to a more anti-inflammatory metabolite profile and enhance the anti-oxidative capacity of the heart. |
| T741 |
2116-2333 |
Sentence |
denotes |
Despite these promising effects of n-3 PUFAs, more experimental, randomized control trials and epidemiological research is warranted to test and translate these proposed effects in the setting of SARS-CoV-2 infection. |
